Qualigen Therapeutics Inc

NASDAQ:QLGN 3:59:43 PM EDT

2.09

-0.06 (-2.79%)

Market Cap (Intraday)	60.26M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$1.7 Million
Adjusted EPS	-$0.18

See more estimates

10-Day MA	$2.08
50-Day MA	$2.00
200-Day MA	$3.34

See more pivots

Qualigen Therapeutics Inc Stock, NASDAQ:QLGN

1880 Century Park East, Suite 3000, Los Angeles, California 90067

United States of America

Phone: +1.310.203.1000

Number of Employees:

http://www.qualigeninc.com

Description

Qualigen Therapeutics, Inc. is a biotechnology company focused on developing therapeutics for the treatment of cancer and infectious diseases. The company's cancer therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F3 and STARSâ„¢. ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug candidate that has the potential to target various types of cancer with minimal side effects. RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA-based treatment device for removal from circulating blood of precisely targeted tumor-produced and viral compounds. The company was founded on March 29, 2004 and is headquartered in Los Angeles, CA.